Financial Performance and Key Metrics - In 2025, the company achieved total revenue of $959.5 million, representing a 61.4% year-over-year increase, with gross profit more than doubling [33][34] - Adjusted net profit reached nearly $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - The adjusted gross profit margin was stable at 51.2%, with adjusted gross profit growing 12.5% year-over-year to $267.3 million [39] Business Segment Performance - The GenScript Life Science Group generated revenue of $522.1 million, growing 14.8% year-over-year, and was identified as the growth engine and profit center [33][38] - ProBio reported total revenue of $388.7 million, with 21% organic growth excluding the LaNova deal, driven by strong customer demand for protein and antibody services [40][41] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Performance - The North American and European markets contributed 38% of total revenue, indicating a notable increase in the company's international footprint [41] - The Asia Pacific region, particularly Greater China, showed increased activity, contributing to the overall growth [10] Company Strategy and Industry Competition - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform leadership, ecosystem expansion, and automation-driven scale [44] - The strategy includes strengthening global partnerships, enhancing customer reach, and integrating new modalities into existing platforms [44] - The company is committed to maintaining its competitive edge through strategic investments in R&D and operational efficiency improvements [54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the CRO and CDMO sectors, citing a rebound in global biopharmaceutical investment and financing [59] - The company anticipates revenue growth for the GenScript Life Science Group to be between 15% and 18% in 2026, with an adjusted gross margin expected to reach 52% [44] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [6] - The company reported a share loss of $310.4 million related to its investment in Legend Biotech, which is expected to improve as Legend's financial position strengthens [34][37] Q&A Session Summary Question: Revenue recognition from LaNova deal - Management confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [48][50] Question: Profitability and gross profit margin decline - Management acknowledged slight fluctuations in gross profit margins due to investments in global expansion and emphasized a focus on cost optimization and operational efficiency to improve profitability [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and improved capacity utilization in China [59][62] Question: Future strategy for Legend Biotech - Management highlighted Legend Biotech's significant progress and profitability, stating that they are not planning to establish new biotech companies but will leverage existing platforms to accelerate drug discovery [64][66] Question: Mitigating customer concerns regarding regulatory scrutiny - Management clarified that the company provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Core Viewpoint - The article emphasizes the importance of professional empowerment and sincere communication in enhancing corporate governance and building long-term trust with investors, particularly through the role of a company secretary [1][3][13]. Group 1: Company Overview - Nanling Technology, established in 1996 and listed on the A-share market in 2020, is the first A-share listed company in the IP-VPN virtual private network service sector, aiming to become a trusted leader in cloud intelligence and network security integration services [7]. - The company has developed innovative products such as SD-WAN, SASE, and zero trust solutions, recognized as market leaders in various IDC reports [8]. Group 2: Performance and Financials - In Q1 2025, Nanling Technology reported a revenue of 131 million yuan and a net profit of 3.33 million yuan, marking a significant year-on-year increase of 174.7%. The operating cash flow turned positive, reaching 12.88 million yuan, a 220.7% increase year-on-year [9]. - The company maintains a low debt-to-asset ratio of 14.7% and a current ratio of 6.88, indicating strong financial health [9]. Group 3: Strategic Initiatives - The company is focused on digital transformation and governance optimization, implementing a three-in-one governance mechanism and a smart risk control system to drive high-quality development [4][9]. - Nanling Technology is actively exploring AI applications and has integrated multiple AI models into its services, enhancing operational efficiency and customer solutions [10]. Group 4: Ecosystem Collaboration - As of Q1 2025, Nanling Technology has signed over 70 channel partners, including telecom operators and cloud service providers, transitioning from project-based cooperation to product-level collaboration [11][12]. - This shift aims to provide diversified, high-quality integrated solutions for state-owned enterprises and large industry players, enhancing technical content and service quality [12]. Conclusion - The company is committed to becoming a leading enterprise in cloud intelligence and network security integration services in China, driven by professional empowerment and sincere communication [14].